Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
BriaCell Therapeutics (Nasdaq:BCTX) closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, for approximately $4.7 million in gross proceeds.
According to BriaCell, net proceeds will support working capital, general corporate purposes, and advancement of business objectives.
BriaCell (Nasdaq:BCTX) reported Phase 2 and ongoing Phase 3 data for its Bria-IMT™ + checkpoint inhibitor regimen in heavily pretreated metastatic breast cancer at ASCO 2026.
Phase 2 Phase 3–regimen patients showed median OS of 16.6 months, >55% 1‑year and >27% 2‑year survival, with favorable safety, preserved quality of life, and blood-based biomarker correlations with progression-free survival.
BriaCell Therapeutics (Nasdaq:BCTX) priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, for expected gross proceeds of about $4.7 million before fees. Closing is expected on June 2, 2026, subject to customary conditions.
Net proceeds are intended for working capital, general corporate purposes, and advancing business objectives. ThinkEquity is sole placement agent. The offering uses BriaCell’s effective Form S-3 shelf registration.
BriaCell (Nasdaq:BCTX) reported that an independent Data Safety Monitoring Board issued a sixth consecutive positive recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT plus checkpoint inhibitor in metastatic breast cancer.
The DSMB found no safety concerns and advised continuing the Fast Track-designated trial without modifications.
BriaCell (Nasdaq:BCTX) reported new Bria-IMT clinical and biomarker data at ASCO 2026 in heavily pretreated metastatic breast cancer.
Final Phase 2 results show median overall survival of 16.6 months for the formulation selected for Phase 3, with 52% 12‑month survival and a tolerable safety profile.
Ongoing Phase 3 data indicate largely preserved quality of life and treatment tolerability and support potential decentralized, home self-administration. Blood-based biomarkers (DTH, CTCs, CAMLs, PD-L1 dynamics) showed correlations with survival and outcomes, pending prospective validation.
BriaCell (Nasdaq:BCTX) is expanding its pipeline into ovarian cancer with Bria-OVA+™, a personalized, off-the-shelf, cell-based immunotherapy candidate. Bria-OVA+ is designed with extra immune-stimulating components and builds on the Bria-OTS+™ platform used in metastatic breast cancer.
Preclinical data from related candidate Bria-BRES+™ showed activation of adaptive and innate immunity, supporting platform potential. BriaCell has licensed ovarian cancer cell lines from ATCC and begun development activities for Bria-OVA+ for potential clinical use.
BriaCell (Nasdaq:BCTX) completed manufacturing clinical supplies of Bria-PROS+™, its next-generation, personalized, off-the-shelf cell-based immunotherapy candidate for prostate cancer. A $2 million non-dilutive NCI grant awarded in August 2025 supports manufacturing and planned clinical evaluation.
The company plans a Phase 1/2a prostate cancer trial in the coming months. Preclinical data show activation of adaptive and innate immunity. Bria-PROS+ leverages the Bria-OTS+ platform, which in breast cancer includes a reported durable complete resolution of a lung metastasis in one patient.
BriaCell (Nasdaq:BCTX) added Penn Medicine’s Abramson Cancer Center as a clinical site for its pivotal Phase 3 Bria-ABC study in advanced metastatic breast cancer.
The trial evaluates lead candidate Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, with overall survival as the primary endpoint and FDA Fast Track designation.
BriaCell (Nasdaq:BCTX) reported that its pivotal Phase 3 Bria-ABC study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer has screened over 315 and enrolled over 230 patients. The trial’s primary endpoint is overall survival, with interim topline data expected in 2026 after 144 events. The Bria-IMT regimen holds FDA Fast Track status and has attracted growing interest from leading cancer centers, including independent highlight in a Nature Medicine article on trials expected to shape medicine in 2026.
BriaCell (Nasdaq: BCTX) added NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center as a clinical site in its pivotal Phase 3 Bria-ABC study for advanced metastatic breast cancer. The trial evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, with overall survival as the primary endpoint and an interim analysis planned after 144 patient events. Bria-IMT has received FDA Fast Track designation. ClinicalTrials.gov identifier: NCT06072612.